UCB and Amgen initiated their sclerostin antibody (CDP7851/AMG 785) Phase III program for the treatment of postmenopausal osteoporosis. The program includes a multicenter, randomized, double-blind, placebo-controlled study in more than 5,000 postmenopausal women with osteoporosis. The primary endpoint will evaluate the incidence of new vertebral fractures at 12 months. CDP7851/AMG 785 is a humanized monoclonal antibody that binds to and inhibits sclerostin, a protein secreted by bone cells that ...